Therapeutic potential of Lachnospiraceae strains in IBS via differential gut-brain pathways
In a murine IBS model with standardized microbiota (SynCom-23), three of four tested Lachnospiraceae strains (B. wexlerae, R. faecis, C. eutactus) reportedly favored intestinal and gut-brain outcomes, while D. longicatena showed neutral or mixed effects; no human clinical data were generated.
| Outcome | Grade | Direction | Effect | Studies |
|---|---|---|---|---|
| Core IBS symptoms (motility and visceral hypersensitivity) | D | — Insufficient | not reported | — |
| Intestinal inflammation | D | — Insufficient | not reported | — |
| Intestinal barrier integrity | D | — Insufficient | not reported | — |
| Oxidative stress | D | — Insufficient | not reported | — |
| Gut microbiota and metabolites | D | — Insufficient | not reported | — |
| Brain neurotransmitters (gut-brain axis) | D | — Insufficient | not reported | — |
Context
IBS affects 5–10% of the global population, with suboptimal treatment options. The Lachnospiraceae family shows altered abundance in IBS patients, but sequencing data are conflicting regarding individual strain roles. Identifying which strains exert beneficial effects — and through which gut-brain axis mechanisms — is a prerequisite for targeted microbial therapy development.
What the study showed
The full text provided does not contain a Results section with primary numerical data — methods and introduction are repeated across all three supplied sections. No absolute values, relative values, 95% CIs, or effect sizes can be extracted from the submitted material. The introduction cites prior animal studies (external references) showing B. wexlerae and R. faecis alleviate IBS symptoms, and notes D. longicatena has a mixed profile due to gas production. Results from the current experiment are not available in the provided text.
How it was done
Preclinical murine IBS model study with defined microbiota background (SynCom-23); four Lachnospiraceae strains administered individually. Endpoints included IBS symptoms, inflammation, oxidative stress, intestinal barrier, microbiota/metabolites, and brain neurotransmitters. Sample size, intervention duration, and complete methodological details are absent from the provided text.
Effect magnitude
Not calculable: no primary or secondary outcome numerical data were available in the provided text. 95% CIs and effect sizes cannot be reported.
Limitations
Critical limitation of this report: the provided full text is a triplicate repetition of the introduction and partial methods, with no results or data-containing discussion section. Risk of bias tools (RoB 2 or SYRCLE for animal studies) cannot be applied without data access. A priori, the SynCom-23 animal model has limited external validity for humans; absence of pharmacokinetic and safety data restricts any clinical inference.
In clinical practice
This study does NOT support any clinical recommendation: it is preclinical (murine) research and outcome data were not available in the analyzed text. Clinicians should not extrapolate findings to IBS patient prescriptions or supplementation. Complete primary data publication must be awaited before any translational consideration.
What is still missing
Publication of complete primary data (results and discussion) is required for critical appraisal. Subsequently, phase I/II clinical trials in human IBS patients are needed to evaluate safety, efficacy, and gut-brain axis mechanisms in relevant populations.